Table 2.

Description of clonal hematopoiesis variants identified on FM testing and confirmed in blood samples

Patient numberAgeSexPrimary tumorTesting interval (days)GeneVariantCOSMIC H/L countaFM VAFUNCseq tumor VAFUNCseq or MCC blood VAF
UNC0165FOvarian30TP53R280G831.83.2
UNC0257FMeningioma1,412TET2T940fs*1318.81.99.7
UNC0364FOvarian721DNMT3AR882C45721.912
UNC0471MPancreatic−24NRASG12D618115.229
UNC0554FCarcinoma NOS3DNMT3AG550Rb832.39
UNC0684FLung788PTPN11V428Mc00.7801.4
MCC0168FBreast2,194DNMT3AR736C212.1NA3
MCC0249FBreast−60DNMT3AR635W182NA5
MCC0358MColorectal−294TET2R1452*172NA3
MCC1084MLung−195DNMT3AW314*115NA43
MCC1264MSarcoma−46DNMT3AI670fs*3506NA13
MCC1475FLung−57DNMT3AR882C4571.7NA4
MCC1578MLung0SF3B1K666N905.5NA8.1
MCC1656MBrain12CBLL380P241.3NA2.5
MCC2281FLung−333TP53P177R01NA2.7
MCC2478MBrain−38CBLC401Y35.5NA11.5
MCC2478MBrain−38TET2H1904R817.4NA71.7
MCC2776MLung−28SF3B1Y623C93.6NA36.8
  • NOTE: For testing interval, negative numbers mean that FM testing preceded UNCseq or MCC testing, and positive numbers mean that UNCseq or MCC testing preceded FM. Age is at the time of FM testing.

  • Abbreviation: NOS, not otherwise specified.

  • aRepresents the number of times this amino acid variant was reported in the COSMIC database, in the “haematopoietic and lymphoid” (H/L) category, v85 (released May 8, 2018).

  • bListed as a variant of uncertain significance.

  • cVariant was reported on FoundationACT testing, which is an assay for circulating tumor DNA.